Singular Genomics Systems, Inc. to Report Third Quarter 2021 Financial Results on November 9, 2021
Singular Genomics Systems will report its Q3 2021 financial results after market close on November 9, 2021. Management will host a conference call at 1:30 PM PT to discuss these results. Singular Genomics focuses on advancing genomic technologies, offering products like the Singular Sequencing Engine and developing integrated solutions such as the G4 Integrated Solution for NGS and the PX Integrated Solution for multiomics applications.
- Development of G4 Integrated Solution targeted at NGS market.
- Advancement of PX Integrated Solution combining multiple analysis methods.
- None.
LA JOLLA, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc., a company focused on delivering genomic technologies for the advancement of science and medicine, today announced that it will report financial results for the third quarter of 2021 after the market close on Tuesday, November 9, 2021. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at investor.singulargenomics.com, in the News & Events section.
About Singular Genomics Systems, Inc.
Singular Genomics is a life science technology company that is leveraging novel, next generation sequencing (NGS) and multiomics technologies to build products that empower researchers and clinicians. Our mission is to accelerate genomics for the advancement of science and medicine. Our Singular Sequencing Engine is the foundational platform technology that forms the basis of our products in development as well as our core product tenets: accuracy, speed, flexibility, and scale. We are currently developing two integrated solutions that are purpose built to target applications in which these core product tenets matter most. Our first integrated solution, the G4 Integrated Solution, is targeted at the NGS market. Our second integrated solution in development, the PX Integrated Solution, combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument to offer a versatile multiomics solution. The G4 and PX Integrated Solutions are both comprised of an instrument and an associated menu of consumable kits.
Investor Contact
Matt Clawson
949-370-8500
ir@singulargenomics.com
Media Contact
Dan Budwick, 1AB
973-271-6085
dan@1abmedia.com
FAQ
When will Singular Genomics report its Q3 2021 financial results?
What time is the Singular Genomics Q3 2021 earnings call?
What products is Singular Genomics currently developing?
